Literatur
- 1
Heidrich J, Liese A D, Kalic M. et al .
Sekundärprävention der koronaren Herzkrankheit - Ergebnisse der Euroaspire I- und
II-Studien in der Region Münster, Germany. Secondary prevention of coronary heart
disease. Results from EuroASPIRE I and II in the region Munster, Germany.
DMW.
2002;
127
667-672
- 2
Jost A, Rauch B, Hochadel M. et al .
Beta-blocker treatment of patients with chronic systolic heart failure improves prognosis
even in patients meeting one or more exclusion criteria of the MERIT-HF study.
Eur Heart J.
2005;
26
2689-2697
- 3
MERIT-HF Study Group .
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention
Trial in Congestive Heart Failure (MERIT-HF).
Lancet.
1999;
353
2001-2007
- 4
Bertrand M E, Simoons M C, Fox K. et al .
Management of acute coronary syndromes in patients presenting without persistent ST-segment
elevation. The Task Force on the Management of Acute Coronary Syndromes of the European
Society of Cardiology.
Eur Heart J.
2002;
23
1809-1840
- 5
Hunt S A, Baker D W, Chin M H. et al .
ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the
Adult: Executive Summary. A Report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995
Guidelines for the Evaluation and Management of Heart Failure).
Circulation.
2001;
104
2996-3007
- 6
Leon A S, Franklin B A, Costa F. et al .
Cardiac Rehabilitation and Secondary Prevention of Coronary Heart Disease. An American
Heart Associations Scientific Statement From the Counsil on Clinical Cardiology (Subcommittee
on Exercise, Cardiac Rehabilitation and Prevention) and the Counsil on Nutrition,
Physical Activity, and Metabolism (Subcommitte on Physical Activity), in Collaboration
with the American Association of Cardiovascular and Pulmonary Rehabilitation.
Circulation.
2005;
111
369-376
- 7
Swedberg K, Metra M, Cleland J. Task Force for the Diagnosis and Treatment of Chronic
Heart Failure of the European Society of Cardiology. .
Guidelines for the diagnosis and treatment of chronic heart failure.
Eur Heart J.
2005;
26
1115-1140
- 8
Williams M A, Fleg J L, Ades P A. et al .
Secondary prevention of coronary heart disease in the elderly (with emphasis on patients
≥ 75 years of age): an American Heart Association scientific statement from the Council
on Clinical Cardiology Subcommittee on Exercise, Cardiac rehabilitation, and Prevention.
Circulation.
2002;
105
1735-1743
- 9
Verschuren W M, Jacobs D R, Bloemberg B P. et al .
Serum total cholesterol and long-term coronary heart disease mortality in different
cultures. Twenty-five-year follow-up of the seven countries study.
JAMA.
1995;
274
131-136
- 10
Cullen P, Funke H, Schulte H, Assmann G.
Lipoproteins and cardiovascular risk - from genetics to CHD prevention.
Eur Heart J.
1998;
19 (Suppl C)
C5-C11
- 11
LaRosa J C, He J, Vupputuri S.
Effect of Statins on Risk of Coronary Disease - a metaanalysis of randomized controlled
trials.
JAMA.
1999;
282
2340-2346
- 12
LaRosa J C, Grundy S M, Waters D D. et al .
for the Treating to New Targets (TNT) Investigators. Intensive Lipid Lowering with
Atorvastatin in Patients with Stable Coronary Disease.
New Engl J Med.
2005;
352
1425-1435
- 13
Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A.
Non-lipid-related effects of statins.
Ann Med.
2000;
32
164-176
- 14
Jochmann N, Stangl K, Garbe E, Baumann G, Stangl V.
Female-specific aspects in the phyarmacotherapy of chronic cardiovascular diseases.
Eur Heart J.
2005;
26
1585-1595
- 15
Van den Hoogen P C, Feskens E J, Nagelkerke N J, Menotti A, Nissinen A, Kromhout D.
The relation between blood pressure and mortality due to coronary heart disease among
men in different parts of the world. Seven countries study research group.
New Engl J Med.
2000;
342
1-8
- 16
Franco V, Oparil S, Carretero O A.
Hypertensive Therapy: Part II.
Circulation.
2004;
109
3081-3088
- 17
European Society of Hypertension .
European Society of Hypertension - European Society of Cardiology Guidelines for the
Management of Arterial Hypertension.
J Hypertens.
2003;
21
1011-1053
- 18
Franco V, Oparil S, Carretero O A.
Hypertensive Therapy: Part I.
Circulation.
2004;
109
2953-2958
- 19
Dahlöf B, Sever P S, Poulter N R. et al .
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine
adding perindopril as required versus atenolol adding bendroflumethiazide as required,
in the Anglo-Scandinavian Cardiac Outsomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA):
a multicentre randomized controlled trial.
Lancet.
2005;
366
895-906
- 20
Wachtell K, Lehto M, Gerdts E. et al .
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent
stroke compared to atenolol. The Losartan Intervention For End point reduction in
hypertension (LIFE) study.
J Am Coll Cardiol.
2005;
45
712-719
- 21
UK Prospective Diabetes Study Group .
UKPDS 39. Efficacy of atenolol and captopril in reducing risk of macrovascular and
microvascular complications in type 2 diabetes: UKPDS 39.
BMJ.
1998;
317
713-720
- 22
Tabacova S, Little R, Tsong Y, Vega A, Kimmel C A.
Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment.
Pharmacoepidemiology and drug safety.
2003;
12
633-646
- 23
Grundy S M, Benjamin E J, Burke G L. et al .
Diabetes and Cardiovascular Disease. A Statement for healthcare Professionals From
the American Heart Association.
Circulation.
1999;
100
1134-1146
- 24 Standl E, Eckert S, Fuchs C. et al .Diabetes-Leitlinie (DDG) „Diabetes und Herz”. 2002
- 25
Dormandy J A, Charbonnel B, Eckland D JA. et al for the PROactive investigators .
Secondary prevention of macrovascular events in patients with type 2 diabetes in the
PROactive Study (PROspective piogliAzone Clinical Trial In macroVascular Events):
a randomized controlled trial.
Lancet.
2005;
366
1279-1289
- 26
Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M.
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis
of seven longterm studies.
Eur Heart J.
2004;
25
10-16
- 27
Gelfand E V, Cannon C P.
Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic
risk factors.
J Am Coll Cardiol.
2006;
47
1919-1926
- 28
Kyrou I, Valsamakis G, Tsigos C.
The endocannabinoid system as a target for the treatment of visceral obesity and metabolic
syndrome.
Annals of the New York Academic of Sciences.
2006;
1083
270-305
- 29
Hoppe U C, Erdmann E.. Vorstand der Deutschen Gesellschaft für Kardiologie- Herz-
und Kreislaufforschung (Hrsg), bearbeitet im Auftrag der Kommission für Klinische
Kardiologie in Zusammenarbeit mit der Arzneimittelkommission der Deutschen Ärzteschaft
.
Leitlinien zur Therapie der chronischen Herzinsuffizienz.
Z Kardiol.
2001;
90
218-237
- 30
Fox K A, Mehta S R, Peters R. et al .
Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing
surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel
in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
Circulation.
2004;
110
1202-1208
- 31
Masoudi F A, Havranek E P, Smith G. et al .
Gender, age, and heart failure with preserved left ventricular sysolic function.
J Am Coll Cardiol.
2003;
41
217-223
- 32
Hulley S, Grady D, Bush T. et al .
Randomized trial of estrogen plus progestin for secondary prevention of coronary heart
disease in postmenopausal women. Heart and estrogen/progestin Replacement Study (HERS)
Research Group.
JAMA.
1998;
280
605-613
- 33
Waters D D, Alderman E I, Haia J. et al .
Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary
atherosclerosis in postmenopausal women: a randomized controlled trial.
JAMA.
2002;
288
2432-2440
- 34
Erstpublikation in: Rauch B et al.
Kardiologische Rehabilitation.
Thieme.
2007;
Dr. med. Alessandra Boscheri
Medizinische Klinik/Kardiologie
Technische Universität Dresden
Fetscherstraße 76
01309 Dresden
eMail: Alessandra.Boscheri@mailbox.tu-dresden.de
